Q2 2023 CarelonRx Drug and Biologic Pipeline Update

We publish the CarelonRx Drug and Biologic Pipeline Update each quarter to keep you informed about upcoming Food and Drug Administration (FDA) approvals. This newsletter analyzes drugs and biologics in development and other clinical topics of interest.

Download the PDF to learn about:

1.  Three agents with the potential to reach the market this year for Demodex blepharitis, nonalcoholic steatohepatitis (NASH), and primary hyperoxaluria.

2.  Other significant treatments expected in the next few years, including gene therapies and biosimilars.

3.  Summary of the Food and Drug Administration (FDA) 2022 approvals, the respiratory syncytial virus (RSV) therapy pipeline, and an update on beta-amyloid agents for Alzheimer’s disease.